It looks like that oncology is very hot topic for Big Pharma!
"There are a large number of drugs being developed in oncology," said Dr. Richard Pazdur, head of the FDA's office of oncology products. "There is greater understanding of some of the disease processes."
Last year, 10 out of 30 new drugs approved by the FDA were for treatment of cancer.
"This year we expect over 20 oncology applications will be filed," Pazdur said in an interview at a meeting of the American Society of Clinical Oncology in Chicago.
So far this year, cancer drugs approved by the FDA include Roche's Erivedge for basal cell carcinoma; Pfizer's Inlyta for kidney cancer; GlaxoSmithKline's Votrient for soft tissue sarcoma; and Leo Pharma's Picato for actinic keratosis.
Well, why not? Just to get approved really effective new drugs, especially were needs are very unmet: brest, lung, prostate and colon cancer...
No comments:
Post a Comment